Interview with Thierry Teil, Managing Director, UCB Russia
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Address: Shabolovka str. 10Building 2, floor 3RUS – 119048 Moscow,Russia
Tel: +7 495 644 3322
Web: http://www.ucb.com/worldwide/Russia
UCB started operations in 1994, and after 2 partnering agreements, started local activities in 2005, further building its presence with Schwarz Pharma integration in 2007
UCB has two legal entities based in Moscow
– UCB Russia LLC
– UCB pharma Logistics LLC
Around 200 employees in 2011
UCB has representatives in the top 26 cities of Russia
In-market sales ~EURO 48 M in 2010
New legal entity: UCB Pharma Logistics
– Registred in 2010, Licenses granted, operational start in May. 2011
– Importation of UCB products in Russia and sales to distributors
– Partnership with a Russian distribution company FARMAT
Local manufacturing and packaging with Binnopharm
– Secondary packaging for a selected few products at the beginning
– Primary and secondary packaging planned
– Local manufacturing planned for later
– On-going finalization for this partnership on Local production, marketing and sales.
UCB Mature Products Continue to Improve Patients Outcome:
– Keppra :
Acknowledged worldwide as a landmark in the treatment of epilepsy, Keppra® is contributing to the wellbeing of thousands of Russian patients with epilepsy
-Xyzal and Zyrtec:
Bringing relief to patients with allergies, from allergic rhinitis to Chronic urticaria, in children and adults
-Isoket:
Leading nitrates in Russia for the treatment of angina pectoris with particularly helpful use in ambulances for Isoket ® spray
-Prostavasin:
Market leading treatment in conjunction to surgery for patients with Advanced Peripheral Obstructive Arterial disease as an alternative to amputation
All UCB Core Products in Russia: 2010-2011
UCB is becoming the Patient-Centric global biopharmaceutical leader
-Cimzia:
Fast response for predictable outcomes
-Vimpat:
When monotherapy is no longer enough
Launch in Russia in Sept 2010Already more than 300 severe epileptic patients treated
-Neupro:
24h continuous delivery by transdermal patch
Approval in Russia expected in July 2011 for Parkinson Disease
On-going launch following Phase 3 in Russia that has proven Cimzia’s benefit locallyNew treatment opportunity for patients with RA
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here